Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 100 clinical trials
manual trial test  

manual trial test overview

  • 0 views
  • 09 Jul, 2026
  • 11 locations
Analytics Tab Trial 001  

Test Comment here...

  • 0 views
  • 19 Feb, 2024
  • 1 location
Build 2 Testing DQ Trail 001  

Test Comment here Please ignore this..

  • 0 views
  • 10 Jan, 2025
  • 1 location
  • 0 views
  • 19 Feb, 2024
  • 1 location
Perceptions of Vaping Products  

This clinical trial studies the effects, appeal, and abuse liability of 6-methyl nicotine (metatine) electronic cigarettes among young adults.

Accepts healthy volunteers
  • 0 views
  • 11 Mar, 2025
  • 2 locations
Comparative Efficacy of Pregabalin and Lacosamide in Patients With Herpes Zoster and Post Herpetic Neuralgia  

Post-herpetic neuralgia (PHN) is the most significant complication of herpes zoster caused by reactivation of latent Varicella-Zoster virus (VZV). PHN is characterized by neuropathic pain lasting beyond the resolution of the rashes. Post herpetic neuralgia (PHN) represents a potentially debilitating and often undertreated form of neuropathic pain that disproportionately affects …

  • 0 views
  • 03 Dec, 2025
  • 1 location
Test trial v7.2 changes  

Testing

Accepts healthy volunteers
  • 0 views
  • 25 Jun, 2025
Study for Acne  

test123-publish Study for Acne

Accepts healthy volunteers
  • 0 views
  • 14 Jul, 2026
  • 2 locations
Meal Response, Protein, and PCOS  

Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by insulin resistance, hyperandrogenism, and reproductive dysfunction. Dietary strategies that improve postprandial insulin and glucose responses are central to managing metabolic symptoms in PCOS. Protein-rich meals can attenuate postprandial glycemia and enhance satiety, but the effects may vary by protein …

  • 0 views
  • 16 Jul, 2026
  • 4 locations
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease (POINT-HD)  

This is a first-in-human (FIH) study of RG6496 that will assess the safety and tolerability of single-ascending doses of RG6496 administered to huntington's disease gene expansion carriers (HDGECs). The study consists of two parts: Part 1 [single-ascending dose] followed by Part 2 [open-label extension (OLE)].

  • 0 views
  • 29 Nov, 2025
  • 1 location